Drugs / HFO-1234ze
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05755932 | Jun 2023 → Jul 2024 | mucus inspissation of respiratory tract | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HFO-1234ze | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05755932 ↗ |
| Known as | hydrofluoroolefin-1234ze | “lower-GWP propellants, such as hydrofluoroolefin-1234ze (HFO-1234ze), which has 99% lower GWP than HFA-134a.” PMID 42461285 ↗ Jul 2026 |
| Route | Inhaled | “Route of administration: Oral inhalation” NCT05755932 ↗ |